7634.T
The company operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to customers in Japan and internationally.
Business. The company operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to customers in Japan and internationally.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to customers in Japan and internationally.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥10,625,818,000, which significantly exceeds its total liabilities of ¥6,160,428,000. The current ratio of 3.17 indicates a robust ability to meet short-term obligations. Additionally, the company's free cash flow of ¥1,537,807,000 supports its operational flexibility and capacity for reinvestment.
In terms of profitability, the company's return on equity (ROE) of 7.94% and return on assets (ROA) of 5.95% are indicative of efficient use of equity and assets to generate profits. These figures align with the industry's preferred metrics, suggesting the company is performing in line with its peers. The operating income of ¥1,981,397,000 and net income of ¥1,463,494,000 further support the company's profitability.
The company's revenue is primarily concentrated in Japan, with a significant portion derived from domestic operations. While the company has a presence in international markets, the majority of its revenue is generated within Japan, which may expose it to regional economic fluctuations.
The company's growth trajectory is supported by its consistent revenue and earnings performance. The operating cash flow of ¥2,194,439,000 and capital expenditure of -¥549,853,000 indicate a balance between reinvestment and cash generation. The company's outlook for the current fiscal year suggests continued growth, with a focus on maintaining profitability and expanding its market share.
The company's risk assessment indicates a low level of liquidity and dilution risk. The absence of immediate filing-based liquidity or dilution flags suggests that the company is not currently facing significant financial pressures. The low dilution potential and the absence of adjustments in the custom valuations further support this assessment.
Recent events, including the latest financial filings and transcripts, have not indicated any material changes in the company's operations or financial health. The company's management has emphasized maintaining a strong balance sheet and exploring opportunities for growth within the healthcare sector.
- The company has a strong liquidity position with a current ratio of 3.17 and significant cash reserves.
- Profitability metrics such as ROE and ROA are in line with industry standards, indicating efficient operations.
- Revenue is primarily concentrated in Japan, which may pose regional economic risks.
- The company's growth is supported by consistent cash flow and a balanced approach to capital expenditure.
- Low liquidity and dilution risks suggest a stable financial position with no immediate concerns.
- **margin_outlook_rationale**: The company's gross profit margin is expected to remain stable due to consistent cost management and pricing strategies.
- **rd_outlook_rationale**: Research and development expenditures are expected to remain moderate, focusing on incremental improvements in existing products.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 7634.T Market data — financials · 2026-05-27
- Hoshi Iryo-Sanki Co Ltd Market data — analyst estimates · 2026-05-27